Amylyx Pharmaceuticals grabs USD 30 Million
Amylyx Pharmaceuticals has grabbed USD 30 million boosts after posting positive data, which showed it could help decrease amyotrophic lateral sclerosis (ALS).
AMX0035, which is its leading candidate, is being tested in degenerative ALS and Alzheimer’s disease. However, the drug lately came through the so-called CENTAUR test, indicating it could slow disease progression when compared to placebo.
The full data from the phase 2 trial are anticipated soon but, in the meantime, Amylyx is also working on a mid-stage trial for the drug called PEGASUS in Alzheimer’s, with top-line data scheduled for the first quarter ...
